Detection of circulating tumor cells in metastatic breast cancer patients

Sanislo, L; Vertáková-Krakovská, Bibiana; Kuliffay, P; Brtko, Július; Galbavý, Š

doi:10.4149/endo_2011_03_113

Cited by 4 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Circulating tumor cells (CTCs) are typically identified in approximately 50-80% of patients with defined metastatic breast, colon, or prostate cancer. 28,29 Whether the remaining patients have CTCs that are either too rare to be captured, lack the surface markers for capture, or may not be present in the blood stream (e.g., the metastatic cells have remained solely in the tissue or lymphatics) is currently unknown. For those patients with detectable CTCs, the surface antigens currently used clinically to select these cells are epithelial cell adhesion molecule (EpCAM), cytokeratin-19 30,31 and MUC1.…”

Section: Muc1 Expression Correlates With Metastasismentioning

confidence: 99%

MUC1 and metastatic cancer

Horm

Schroeder

2013

Cell Adhesion & Migration

159

View full text Add to dashboard Cite

Section: Muc1 Expression Correlates With Metastasismentioning

confidence: 99%

MUC1 and metastatic cancer

Horm

Schroeder

2013

Cell Adhesion & Migration

159

View full text Add to dashboard Cite

“…Patients with breast cancer expressing CK19, SCGB2A2, and ERBB2 showed poor survival rates. [22] Riethdrof et al [23] demonstrated that HER2+ CTCs can be identified in HER2-breast cancer patients, leading to consideration of revision of ongoing treatment, with trastuzumab-based therapy applied to patients with HER2+ CTCs and HER2-primary tumors, demonstrating that CTCs can assist in determining the changing course of disease in a timely manner and have potential to determine the metastatic state of breast cancer.…”

Section: Introductionmentioning

confidence: 99%

“…The majority of CTCs isolated from breast cancer patients express EMT markers, including ETV5, NOTCH1, SNAIL, TGFB1, ZEB1, and ZEB2. [21] Keratin analysis is also a major molecular test in cancer, while CK19 and TP53 mutations are frequently found in CTCs from triple-negative breast cancer patients, [22] and are a factor in the progression of the disease to the triple-negative stage. Patients with breast cancer expressing CK19, SCGB2A2, and ERBB2 showed poor survival rates.…”

Section: Introductionmentioning

confidence: 99%

Profiling of circulating tumor cells in liquid biopsies from metastatic cancer patients

Potdar¹,

Sen²

2017

JCMT

View full text Add to dashboard Cite

Aim: Circulating tumor cells (CTCs) are crucial to tumor metastasis and valuable for prediction of clinical outcome in patients with solid tumors. Here, the authors aimed to establish a method for enumeration and characterization of CTCs from liquid biopsies. Methods: Peripheral blood mononuclear cells (PBMCs) were separated from blood samples from patients with metastatic cancer using Ficoll-Hypaque gradients and cultured to isolate and enumerate CTCs. Cultured CTCs were morphologically characterized by light and phase contrast microscopy. The tumorigenicity of Ficoll-Hypaque-separated PBMCs was examined, in addition to their expression of mRNA metastasis markers. Results: CTCs were isolated in culture and enumerated by counting under phase contrast microscopy, demonstrating that 0.01-0.04% of total PBMCs were CTCs. CTCs were dormant, with large, oval-shaped, spiky morphology. PBMCs obtained from liquid biopsies exhibited anchorage-independent growth, forming numerous colonies in soft agar assays. Molecular profiling demonstrated expression of several metastatic genes, but not of cadherin 1 (encoding the adhesion protein), in all patients. Conclusion: The authors successfully isolated, enumerated, and characterized CTCs from liquid biopsies of metastatic cancer patients. This study has potential to facilitate the development of new diagnostic and therapeutic methods using liquid biopsies, for application in metastatic cancers. Key words:Circulating tumor cells, liquids biopsies, molecular markers, soft agar assay, metastasis, metastatic genes, epithelial mesenchymal transition, tumorigenic ABSTRACTArticle history:

show abstract

Laser Scanning Cytometry: Principles and Applications—An Update

Pożarowski

Holden²,

Darżynkiewicz

2012

Methods in Molecular Biology

View full text Add to dashboard Cite

Laser scanning cytometer (LSC) is the microscope-based cytofluorometer that offers a plethora of unique analytical capabilities, not provided by flow cytometry (FCM). This review describes attributes of LSC and covers its numerous applications derived from plentitude of the parameters that can be measured. Among many LSC applications the following are emphasized: (a) assessment of chromatin condensation to identify mitotic, apoptotic cells, or senescent cells; (b) detection of nuclear or mitochondrial translocation of critical factors such as NF-κB, p53, or Bax; (c) semi-automatic scoring of micronuclei in mutagenicity assays; (d) analysis of fluorescence in situ hybridization (FISH) and use of the FISH analysis attribute to measure other punctuate fluorescence patterns such as γH2AX foci or receptor clustering; (e) enumeration and morphometry of nucleoli and other cell organelles; (f) analysis of progeny of individual cells in clonogenicity assay; (g) cell immunophenotyping; (h) imaging, visual examination, or sequential analysis using different probes of the same cells upon their relocation; (i) in situ enzyme kinetics, drug uptake, and other time-resolved processes; (j) analysis of tissue section architecture using fluorescent and chromogenic probes; (k) application for hypocellular samples (needle aspirate, spinal fluid, etc.); and (l) other clinical applications. Advantages and limitations of LSC are discussed and compared with FCM.

show abstract

Detection of circulating tumor cells in metastatic breast cancer patients

Cited by 4 publications

References 12 publications

MUC1 and metastatic cancer

MUC1 and metastatic cancer

Profiling of circulating tumor cells in liquid biopsies from metastatic cancer patients

Laser Scanning Cytometry: Principles and Applications—An Update

Contact Info

Product

Resources

About